BACKGROUND: Genital tract secretions provide variable inhibitory activity against herpes simplex virus (HSV) ex vivo. We hypothesize that the anti-HSV activity may prevent the spread of virus from the more commonly affected sites, such as the external genitalia, to the upper genital tract. METHODS: The antimicrobial activity of cervicovaginal lavage (CVL) and concentrations of mucosal immune mediators were measured in 10 HIV-seronegative women with an active external herpetic lesion and compared with 10 HIV-seronegative women who were HSV-1 and HSV-2 seronegative. Samples were obtained at the time of a symptomatic external lesion (day 0), after 1 week of oral acyclovir (day 7), and 1 week after completing treatment (day 14). Controls were evaluated at parallel intervals. RESULTS: The anti-HSV activity was higher in CVL obtained from cases compared to controls at presentation (day 0) (54.3% vs. 28%), fell to similar levels on day 7, and then rebounded on day 14 (69% vs. 25%). The anti-HSV activity correlated positively and significantly with the concentrations of several inflammatory proteins; the concentrations of these proteins tended to be higher in cases compared with controls and followed a similar temporal pattern. CONCLUSIONS: Increases in inflammatory immune mediators and anti-HSV activity were detected in CVL at the time of clinical outbreaks and after completion of a short course of acyclovir. These mucosal responses may protect against HSV spread but could facilitate HIV infection and contribute to the clinical observation that, independent of clinical lesions, HSV-2 is a risk factor for HIV acquisition.
BACKGROUND: Genital tract secretions provide variable inhibitory activity against herpes simplex virus (HSV) ex vivo. We hypothesize that the anti-HSV activity may prevent the spread of virus from the more commonly affected sites, such as the external genitalia, to the upper genital tract. METHODS: The antimicrobial activity of cervicovaginal lavage (CVL) and concentrations of mucosal immune mediators were measured in 10 HIV-seronegative women with an active external herpetic lesion and compared with 10 HIV-seronegative women who were HSV-1 and HSV-2 seronegative. Samples were obtained at the time of a symptomatic external lesion (day 0), after 1 week of oral acyclovir (day 7), and 1 week after completing treatment (day 14). Controls were evaluated at parallel intervals. RESULTS: The anti-HSV activity was higher in CVL obtained from cases compared to controls at presentation (day 0) (54.3% vs. 28%), fell to similar levels on day 7, and then rebounded on day 14 (69% vs. 25%). The anti-HSV activity correlated positively and significantly with the concentrations of several inflammatory proteins; the concentrations of these proteins tended to be higher in cases compared with controls and followed a similar temporal pattern. CONCLUSIONS: Increases in inflammatory immune mediators and anti-HSV activity were detected in CVL at the time of clinical outbreaks and after completion of a short course of acyclovir. These mucosal responses may protect against HSV spread but could facilitate HIV infection and contribute to the clinical observation that, independent of clinical lesions, HSV-2 is a risk factor for HIV acquisition.
Authors: F X Mbopi-Kéou; G Grésenguet; P Mayaud; H A Weiss; R Gopal; M Matta; J L Paul; D W Brown; R J Hayes; D C Mabey; L Bélec Journal: J Infect Dis Date: 2000-09-08 Impact factor: 5.226
Authors: S B Mostad; J K Kreiss; A J Ryncarz; K Mandaliya; B Chohan; J Ndinya-Achola; J J Bwayo; L Corey Journal: J Infect Dis Date: 2000-01 Impact factor: 5.226
Authors: Steven J Reynolds; Arun R Risbud; Mary E Shepherd; Jonathan M Zenilman; Ronald S Brookmeyer; Ramesh S Paranjape; Anand D Divekar; Raman R Gangakhedkar; Manisha V Ghate; Robert C Bollinger; Sanjay M Mehendale Journal: J Infect Dis Date: 2003-04-23 Impact factor: 5.226
Authors: Lawrence Corey; Anna Wald; Raj Patel; Stephen L Sacks; Stephen K Tyring; Terri Warren; John M Douglas; Jorma Paavonen; R Ashley Morrow; Karl R Beutner; Leonid S Stratchounsky; Gregory Mertz; Oliver N Keene; Helen A Watson; Dereck Tait; Mauricio Vargas-Cortes Journal: N Engl J Med Date: 2004-01-01 Impact factor: 91.245
Authors: Wei Wang; Sherry M Owen; Donna L Rudolph; Alexander M Cole; Teresa Hong; Alan J Waring; Renu B Lal; Robert I Lehrer Journal: J Immunol Date: 2004-07-01 Impact factor: 5.422
Authors: Niall Buckley; Ashley Huber; Yungtai Lo; Philip E Castle; Kimdar Kemal; Robert D Burk; Howard D Strickler; Mark H Einstein; Mary Young; Kathryn Anastos; Betsy C Herold Journal: Am J Reprod Immunol Date: 2015-12-18 Impact factor: 3.886
Authors: Betsy C Herold; Charlene S Dezzutti; Barbra A Richardson; Jeanne Marrazzo; Pedro M M Mesquita; Colleen Carpenter; Ashley Huber; Nicolette Louissaint; Mark A Marzinke; Sharon L Hillier; Craig W Hendrix Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Laura E Richert-Spuhler; Laura Pattacini; Margot Plews; Elizabeth Irungu; Timothy R Muwonge; Elly Katabira; Nelly Mugo; Adrienne F A Meyers; Connie Celum; Jared M Baeten; Jairam R Lingappa; Jennifer M Lund Journal: AIDS Date: 2019-11-15 Impact factor: 4.177
Authors: Jordan K Kyongo; Tania Crucitti; Joris Menten; Liselotte Hardy; Piet Cools; Johan Michiels; Sinead Delany-Moretlwe; Mary Mwaura; Gilles Ndayisaba; Sarah Joseph; Raina Fichorova; Janneke van de Wijgert; Guido Vanham; Kevin K Ariën; Vicky Jespers Journal: Clin Vaccine Immunol Date: 2015-03-11
Authors: Briana Nixon; Martha Stefanidou; Pedro M M Mesquita; Esra Fakioglu; Theodore Segarra; Lisa Rohan; William Halford; Kenneth E Palmer; Betsy C Herold Journal: J Virol Date: 2013-03-27 Impact factor: 5.103
Authors: Dennis Muñoz Vergara; Lisbeth Berrueta; Colleen Carmody; Xingxing An; Peter M Wayne; Ann Marie Zavacki; Helene M Langevin Journal: Am J Phys Med Rehabil Date: 2020-11 Impact factor: 3.412
Authors: Jeny P Ghartey; Benjamin C Smith; Zigui Chen; Niall Buckley; Yungtai Lo; Adam J Ratner; Betsy C Herold; Robert D Burk Journal: PLoS One Date: 2014-05-07 Impact factor: 3.240